Genmab A/S (NASDAQ:GMAB) is one of the 10 best large cap stocks under $30 with highest upside potential.
On May 27, coverage of Genmab A/S (NASDAQ:GMAB) was resumed by Truist analyst Gregory Renza
The analyst reduced the price target from $48 to $40 and assigned a Buy rating to the stock. He shared an optimistic view about the company following its shift towards a commercially focused business platform. This is backed by three key assets comprising around seven important readouts during 2026.
Pressmaster/ According to Renza, Rina-S and petosemtamab have the potential to be best- or first-in-class in ovarian cancer and HNSCC, respectively, while Epkinly’s DLBCL-2/-4 results are crucial for franchise expansion. Back on April 30, H.C. Wainwright reduced the target price on Genmab A/S (NASDAQ:GMAB) from $40 to $38, leading to an adjusted upside potential in excess of 54%.